Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Trails Edge Capital Partners, LP 13F Holdings -- Portfolio & Top Positions (2026-06-30)

Trails Edge Capital Partners, LP (CIK 2077247) reported $629.9M across 35 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: LBRX ($49.4M, 7.85%), NRIX ($38.2M, 6.06%), IMCR ($33.8M, 5.36%), TRAX ($30.5M, 4.84%), FDMT ($29.6M, 4.70%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1LBRXLB PHARMACEUTICALS INC$49.4M7.85%1.5MAdded
2NRIXNURIX THERAPEUTICS INC$38.2M6.06%1.6MTrimmed
3IMCRIMMUNOCORE HLDGS PLC$33.8M5.36%1.1MAdded
4TRAXFIRST TRACKS BIOTHERAPEUTICS$30.5M4.84%1.5MNew
5FDMT4D MOLECULAR THERAPEUTICS IN$29.6M4.70%2.2MAdded
6BMRNBIOMARIN PHARMACEUTICAL INC$29.3M4.65%512,000New
7DSGNDESIGN THERAPEUTICS INC$29.0M4.60%2.0MAdded
8XENEXENON PHARMACEUTICALS INC$26.6M4.22%440,000Trimmed
9MIRMMIRUM PHARMACEUTICALS INC$26.1M4.15%223,312Trimmed
10CYTKCYTOKINETICS INC$24.5M3.90%288,089Trimmed
11INSMINSMED INC$24.6M3.90%230,331New
12SNDXSYNDAX PHARMACEUTICALS INC$24.3M3.85%1.1MAdded
13NGNENEUROGENE INC$22.5M3.57%714,885Trimmed
14KLRAKAILERA THERAPEUTICS INC$21.7M3.44%984,786New
15RVMDREVOLUTION MEDICINES INC$21.7M3.44%115,750Trimmed
16IKTINHIBIKASE THERAPEUTICS INC$18.4M2.92%9.1MAdded
17INCYINCYTE CORP$17.6M2.79%155,000New
18AVTXAVALO THERAPEUTICS INC$16.5M2.62%891,881New
19MLTXMOONLAKE IMMUNOTHERAPEUTICS$14.6M2.32%750,000New
20SNSEFAETH THERAPEUTICS INC$12.9M2.05%515,335Added
21XFORX4 PHARMACEUTICALS INC$12.0M1.91%2.6MHold
22IRDOPUS GENETICS INC$11.3M1.79%2.7MAdded
23SLGLSOL-GEL TECHNOLOGIES LTD$10.3M1.64%139,445Added
24AURAAURA BIOSCIENCES INC$10.2M1.63%1.4MNew
25IPSCCENTURY THERAPEUTICS INC$10.1M1.61%4.1MAdded

Source: SEC Form 13F filings · as of 2026-06-30